

PATENT

Case Docket No. TRIPEP.23AUSC2

Date: December 10, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Sallberg et al.
Appl. No. : 10/719,619
Filed : November 20, 2003
For : VACCINES CONTAINING
RIBAVIRIN AND METHODS
OF USE THEREOF
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 10, 2003

(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664

TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 in seven (7) pages listing one hundred fifty-two (152) references, seven (7) of which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Sallberg et al.
App. No. : 10/719,619
Filed : November 20, 2003
For : VACCINES CONTAINING RIBAVIRIN
AND METHODS OF USE THEREOF
Examiner : Unknown
Group Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing a total of 152 references. The seven (7) references listed on sheet 1 are enclosed. The remaining references listed on sheets 2 through 7, numbered 1 through 145 are of record in U.S. patent application No. 10/104,966, filed March 22, 2002, which is the parent of this application and is relied upon for an earlier filing date under 35 U.S.C. § 120. Accordingly, copies of references listed on sheets 2 through 7, numbered 1 through 145 are not submitted pursuant to 37 C.F.R. § 1.98(d).


This Information Disclosure Statement is being filed within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/10/03

By: 
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sallberg et al.FILING DATE
November 20, 2003

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	6,653,125	11/25/03	Donnelly et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	2.	WO 98/37180	08/27/98	WIPO				
	3.	WO 99/04008	01/28/99	WIPO				
	4.	WO 99/28482	06/10/99	WIPO				
	5.	WO 01/38360	05/31/01	WIPO				
	6.	WO 01/96875	12/20/01	WIPO				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	7.	Hahm et al., "NS3-4A of Hepatitis C Virus is a Chymotrypsin-Like Protease," Journal of Virology, The American Society for Microbiology, 69(4):2534-2539 (1995).

S:\DOCS\ESF\ESF-7400.DOC
121003

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sällberg et al.FILING DATE
November 20, 2003GROUP
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,946,778	08/07/90	Ladner et al.			
	2	4,950,647	08/21/90	Robins et al.			
	3	5,350,671	09/27/94	Houghton et al.			
	4	5,371,017	12/06/94	Houghton et al.			
	5	5,372,928	12/13/94	Miyamura et al.			
	6	5,585,258	12/17/96	Houghton et al.			
	7	5,589,466	12/31/96	Felgner et al.			
	8	5,597,691	01/28/97	Houghton et al.			
	9	5,670,152	09/23/97	Weiner et al.			
	10	5,670,153	09/23/97	Weiner et al.			
	11	5,679,342	10/21/97	Houghton et al.			
	12	5,683,864	11/04/97	Houghton et al.			
	13	5,698,390	12/16/97	Houghton et al.			
	14	5,712,087	01/27/98	Houghton et al.			
	15	5,712,088	01/27/98	Houghton et al.			
	16	5,712,145	01/27/98	Houghton et al.			
	17	5,714,596	02/03/98	Houghton et al.			
	18	5,728,520	03/17/98	Weiner et al.			
	19	5,756,312	03/26/98	Weiner et al.			
	20	5,766,845	06/16/98	Weiner et al.			
	21	5,767,097	06/16/98	Tam			
	22	5,856,437	01/05/99	Miyamura et al.			
	23	5,863,719	01/26/01	Houghton et al.			
	24	5,871,903	02/16/99	Miyamura et al.			
	25	5,885,799	03/23/99	Houghton et al.			
	26	5,932,556	08/03/99	Tam			
	27	5,942,234	08/24/99	Ralston et al.			
	28	5,959,092	09/28/99	Miyamura et al.			
	29	5,968,775	10/18/99	Houghton et al.			
	30	5,989,905	11/23/99	Houghton et al.			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sällberg et al.FILING DATE
November 20, 2003GROUP
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	31	6,027,729	02/22/00	Houghton et al.			
	32	6,056,961	05/02/00	Lavie et al.			
	33	6,060,068	05/09/00	Doyle et al.			
	34	6,063,380	05/16/00	Chedid et al.			
	35	6,063,772	05/16/00	Tam			
	36	6,071,693	06/06/00	Cha et al.			
	37	6,074,816	06/13/00	Houghton et al.			
	38	6,074,846	06/13/00	Ralston et al.			
	39	6,074,852	06/13/00	Ralston et al.			
	40	6,096,541	08/01/00	Houghton et al.			
	41	6,130,326	10/10/00	Ramasamy et al.			
	42	6,150,087	11/21/00	Chien			
	43	6,150,337	11/21/00	Tam			
	44	6,171,782	01/09/01	Houghton et al.			
	45	6,190,864	02/20/01	Cha et al.			
	46	6,194,140	02/27/01	Houghton et al.			
	47	6,214,583	04/10/01	Cha et al.			
	48	6,235,888	05/22/01	Pachuk et al.			
	49	6,274,148	08/14/01	Ralston et al.			
	50	6,297,370	10/02/01	Cha et al.			
	51	6,303,292	10/16/01	Weiner et al.			
	52	6,312,889	11/06/01	Houghton et al.			
	53	6,514,731	02/04/03	Valenzuela et al.			
	54	6,541,011	04/01/03	Punnonen et al.			
	55	6,555,114	04/29/03	Leroux-Roels et al.			
	56	2002/0004048	01/10/02	Ralston et al.			
	57	2002/0165172 A1	11/07/02	Sällberg et al.			
	58	2002/0183508 A1	12/05/02	Maertens et al.			
	59	2002/0187945 A1	12/12/02	Tam			
	60	2003/0007977	01/09/03	Wheeler et al.			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sällberg et al.FILING DATE
November 20, 2003GROUP
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	61	2003/0008274	01/09/03	Maertens et al.			
	62	2003/0032005	02/13/03	Maertens et al.			
	63	2003/0044774	03/06/03	Valenzuela et al.			
	64	2003/0064360	04/03/03	Maertens et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	65	EP 0 388 232	09/19/90	European Patent Office				
	66	EP 0 414 475	02/27/91	European Patent Office				
	67	WO 91/15575	10/17/91	WIPO				
	68	WO 92/19743	11/12/92	WIPO				
	69	WO 93/00365	01/07/93	WIPO				
	70	WO 93/06126	04/01/93	WIPO				
	71	WO 94/16737	08/07/94	WIPO				
	72	EP 0 450 931	06/12/96	European Patent Office				
	73	WO 96/28162	09/19/96	WIPO				
	74	WO 97/12043	04/03/97	WIPO				
	75	EP 0 543 924	06/18/97	European Patent Office				
	76	WO 97/26883	07/31/97	WIPO				
	77	WO 98/16184	04/23/98	WIPO				
	78	WO 98/16186	04/23/98	WIPO				
	79	EP 0 842 947	05/20/98	European Patent Office				
	80	WO 98/30223	07/16/98	WIPO				
	81	EP 0 693 687	07/28/99	European Patent Office				
	82	EP 0 556 292	12/29/99	European Patent Office				
	83	WO 00/44388	08/03/00	WIPO				
	84	EP 1 034 785	09/13/00	European Patent Office				
	85	EP 0 318 216	08/29/01	European Patent Office				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sällberg et al.FILING DATE
November 20, 2003GROUP
Unknown

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	86	EP 0 398 748	01/09/02	European Patent Office				
	87	WO 02/13855	02/21/02	WIPO				
	88	WO 02/14362	02/21/02	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	89	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Conifrugation does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).
	90	Abrignani et al., "Perspectives for a vaccine against hepatitis C virus," <i>Journal of Hepatology</i> , 31: (suppl. 1):259-263 (1999).
	91	Bartenschlager et al., "Substrate Determinants for Cleavage in cis and in trans by the Hapatitis C Virus NS3 Proteinase," <i>Journal of Virology</i> , pp. 198 - 205, (1995).
	92	Chen et al., "Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , 28(1):219-224 (1998).
	93	Chen et al., "Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery," <i>J. Med. Virol.</i> , 43:223-226 (1995).
	94	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42.11-42.16, p. A949 (date unknown).
	95	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).
	96	Cramp et al., "Hepatitis C Virus-Specific T-Cell Reactivity During Intereron and Ribavirin Treatment in Chronic Hepatitis C," <i>Gastron. Enterol.</i> , 118:346-355 (2000)
	97	Encke et al., "DNA Vaccines," <i>Intervirolgy</i> , 42:117-124, (1999)
	98	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model", <i>Journal of Immunology</i> , 161:4917-4923 (1998).
	99	Diepolder et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> , 346(8981):1006-1007.
	100	Fang et al., "Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level," <i>Journal of Hepatology</i> , 33(5):791-798 (2000).
	101	Forns et al., "Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resalving or persistent infection in chimpanzees," <i>PNAS</i> , vol. 97, no. 24, pp. 13318-113323, (2000).
	102	Gordon et al., "Immune responses to hepatitis C virus structural and nonstructural proteins induced byplasmid DNA immunizations," <i>Journal of Infectious Diseases</i> , 181(1):42-50.
	103	Grakoui et al., "A second hepatitis C virus-encoded proteinase," <i>Proc. Natl. Acad. Sci USA</i> , 90:10583-10587, (1993).
	104	Hsu et al., "Prospects for a Hepatitis C Virus Vaccine", <i>Clin Liver Dis</i> , 3(4):901-915 (1999).
	105	Huffman et al., "In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses," <i>Antimicrob. Agents. Chemother.</i> , 3(2):235 (1973).
	106	Hultgren et al., <i>J. Gen. Virol.</i> , 79:2381-2391 (1998)
	107	Jin et al., "Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA Helicase," <i>Arch. Biochem. Biophys.</i> , 323:47-53 (1995).
	108	Kakumu et al., "Pilot Study of Ribarvirin and Interferon- for Chronic Hepatitis B," <i>Hepatology</i> , 18(2):258-263 (1993).

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

SEE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sällberg et al.FILING DATE
November 20, 2003GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	109	Kato, "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation," <i>Microb. Com. Genomics</i> , 5(3):129-151 (2000).
	110	Kumar et al, "Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation," <i>Journal of Viral Hepatitis</i> , 7:459-465 (2000).
	111	Kwong et al., "Hepatitis C virus NS3/4A protease," <i>Antiviral Res.</i> , 41(1):67-84 (1999).
	112	Kwong et al., "Structure and function of hepatitis C virus NS3 helicase," <i>Curr. Top. Microbiol. Immunol.</i> , 242:171-196 (2000).
	113	Lawrence et al., "Advances in the treatment of hepatitis C," <i>Adv. Intern. Med.</i> , 45:65-105 (2000).
	114	Li et al., "Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation," <i>Science</i> , 288:2219-2222 (2000).
	115	Lohmann et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," <i>Science</i> , 285:110-113, (1999).
	116	Marquardt et al., "Ribavirin inhibits mast cell mediator release," <i>J. Pharmacol. Exp. Therapeutics</i> , 240(1):145-149 (1987).
	117	Marshall et al., "Detection of HCV RNA by the asymmetric gap ligase chain reaction," <i>PCR Methods and Applications</i> , 4(2):80-84 (1994).
	118	Memar O. et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," <i>International Journal of Dermatology</i> , 34(9):597-606 (1995).
	119	Missale et al., "Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response," <i>J. Clin. Invest.</i> , 98(3):706-714 (1996).
	120	Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
	121	Pape et al., "Role of the specific T-cell response for clearance and control of hepatitis C virus," <i>J. Viral. Hepat.</i> , Supp. 6, 1:36-40 (1999).
	122	Peavy et al., "Inhibition of murine plaque-forming cell responses in vivo by ribavirin," <i>J. Immunology</i> , 126(3):861-864 (1981).
	123	Powers et al., "Selective inhibition of functional lymphocyte subpopulations by ribavirin," <i>Antimicrob. Agents. Chemother.</i> , 22(1):108-114 (1982).
	124	Proust B. et al., "Two Successive Hepatitis C Virus Infections in an Intravenous Drug User," <i>Journal of Clinical Microbiology</i> , 38(8):3125-3127 (2000).
	125	Ramasamy et al., "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity," <i>Journal of Medicinal Chemistry</i> , 43(5):1019-1028 (2000).
	126	Sällberg et al., "Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens," <i>Journal of Virology</i> , 71:5295-5303 (1997).
	127	Sällberg and Hultgren, "Vaccines Containing Ribavirin and Methods of use Thereof," U.S. Patent Application Serial No. 09/929,955, filed August 15, 2001.
	128	Sällberg, "A Hepatitis C Virus Non-Structural NS3/4A Fusion Gene," U.S. Patent Application Serial No. 09/930,591, filed August 15, 2001.
	129	Sällberg and Hultgren, "Vaccines Containing Ribavirin and Methods of use Thereof," U.S. Patent Application Serial No. 10/104,966, filed March 22, 2002.
	130	Schulof R. S., "Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinosine in HIV-Infected Homosexual Men," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 3(5):485-492 (1990).
	131	Sidwell et al., "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide," <i>Science</i> , 177(50):705-706 (1972).
	132	Smith et al., "Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the Polyhedrin Gene," <i>Journal of Virology</i> , 46:584 (1983).
	133	Spector et al., "The Antiviral Effect of Zidovudine and Ribavirin in Clinical Trials and the Use of p24 Antigen Levels as a Virologic Marker," <i>Journal of Infectious Diseases</i> , 159(5):822-828 (1989).
	134	Szybalska and Szybalska, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," <i>Proc Natl Acad Sci USA</i> , 48:2026 (1962).
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>		

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUSC2APPLICATION NO.
10/719,619INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Sällberg et al.FILING DATE
November 20, 2003GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	135 Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314:452-454 (1985).
	136 Tam et al., "The Immunomodulatory effects of ribavirin: Recent findings," <i>International Antiviral News</i> , 7/6:99 – 100 (1999) (ABSTRACT).
	137 Tam et al., "Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile," <i>Journal of Hepatology</i> , 30(3):376-382 (1999).
	138 Tan et al., "How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A," <i>Virology</i> , 284(1):1-12 (2001).
	139 Vaitukaitis et al., "A method for producing specific antisera with small doses of immunogen," <i>J. Clin. Endocrinology Metab.</i> , 33(6):988-991 (1971).
	140 Walsh et al., "Update on chronic viral hepatitis," <i>Postgrad Medical Journal</i> , 77(910):498-505 (2001).
	141 Wang et al., "Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3,-d]-4-pyrimidone Nucleosides," <i>J. Med. Chem.</i> , 43(13):2566-2574 (2000).
	142 Zhang et al., "Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," <i>Clin. Diagn. Lab. Immunol.</i> , 7(1):58-63 (2000).
	143 Zhang et al., "Interferon- α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy," <i>The Journal of Infectious Diseases</i> , 175:1294-1301 (1997).
	144 Zhang et al., "Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein," <i>Clin. Exp. Immunol.</i> , 96(3):403-409 (1994).
	145 http://www.msi.com/life/products/cerius2/modules/analogbuilder.html , C2Analog Builder, July 6, 2000.

S:\DOCS\ESF\ESF-7399.DOC
121003

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	